Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:8997 |
Name | polycythemia vera |
Definition | A myeloproliferative neoplasm characterized by erythroid hyperplasia, myeloid leukocytosis, thrombocytosis, and splenomegaly. |
Source | DiseaseOntology.org |
Alt Ids | DOID:11868 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myeloproliferative neoplasm polycythemia vera |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
JAK2 V617F | Ropeginterferon | polycythemia vera | sensitive | detail... |
IDH1 mutant | N/A | polycythemia vera | not applicable | detail... |
IDH2 mutant | N/A | polycythemia vera | not applicable | detail... |
JAK2 V617F | INCB053914 | polycythemia vera | predicted - sensitive | detail... |
JAK2 V617F | N/A | polycythemia vera | not applicable | detail... |
JAK2 exon12 | N/A | polycythemia vera | not applicable | detail... |
JAK2 V617F | C220 | polycythemia vera | predicted - sensitive | detail... |
JAK2 V617F | C220 + Ruxolitinib | polycythemia vera | predicted - sensitive | detail... |
JAK2 V617F | Binimetinib + Ruxolitinib | polycythemia vera | sensitive | detail... |
JAK2 V617F | Binimetinib + CHZ868 | polycythemia vera | sensitive | detail... |
JAK2 V617F | Crizotinib | polycythemia vera | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02038036 | Phase III | Peginterferon alfa-2b Anagrelide Hydroxyurea Pipobroman Ruxolitinib | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2) | Completed | TUR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT02493530 | Phase I | Ruxolitinib + Umbralisib | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | Completed | USA | 0 |
NCT03287245 | Phase II | Idasanutlin | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | Terminated | USA | ITA | CAN | AUS | 0 |
NCT03669965 | Phase II | Ruxolitinib KRT-232 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | Unknown status | USA | POL | HUN | FRA | ESP | DEU | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04041050 | Phase I | Navitoclax Navitoclax + Ruxolitinib | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | Active, not recruiting | USA | TUR | SWE | ITA | HRV | GBR | FRA | ESP | DEU | BGR | BEL | 3 |
NCT04116502 | Phase III | Ruxolitinib Hydroxyurea Alpha 2 Interferon | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (MITHRIDATE) | Recruiting | GBR | 0 |
NCT04262141 | Phase II | IMG-7289 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | Active, not recruiting | USA | 0 |
NCT04282187 | Phase II | Decitabine + Fedratinib Decitabine + Ruxolitinib | Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT04644211 | Phase II | Ruxolitinib | Ruxolitinib in Thrombocythemia and Polycythemia Vera | Recruiting | USA | 0 |
NCT04955938 | Phase I | Enasidenib + Fedratinib Fedratinib + Ivosidenib | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | Withdrawn | USA | 0 |
NCT05127174 | Phase Ib/II | Fedratinib | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | Active, not recruiting | USA | 0 |
NCT05481151 | Phase III | Ropeginterferon | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | Active, not recruiting | USA | CAN | 0 |
NCT05558696 | Phase II | IMG-7289 | Bomedemstat in Patients With Polycythemia Vera | Active, not recruiting | USA | GBR | AUS | 0 |
NCT06093672 | Phase III | Givinostat Hydroxyurea | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera (GIV-IN PV) | Recruiting | USA | POL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | BGR | AUT | 1 |
NCT06218628 | Phase I | Pacritinib + Talazoparib | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | Recruiting | USA | 0 |
NCT06291987 | Phase I | Ivosidenib + Ruxolitinib | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) | Recruiting | USA | 0 |
NCT06343805 | Phase I | AJ1-11095 | A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Recruiting | USA | 0 |
NCT06351631 | Phase III | IMG-7289 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | Recruiting | USA | NZL | ITA | GBR | AUS | 1 |